179 related articles for article (PubMed ID: 35344868)
21. What makes a type IIA topoisomerase a gyrase or a Topo IV?
Hirsch J; Klostermeier D
Nucleic Acids Res; 2021 Jun; 49(11):6027-6042. PubMed ID: 33905522
[TBL] [Abstract][Full Text] [Related]
22. Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
Balsalobre L; Ferrándiz MJ; de Alba G; de la Campa AG
Antimicrob Agents Chemother; 2011 Mar; 55(3):1097-105. PubMed ID: 21173181
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
24. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
25. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
26. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
Tomašić T; Mašič LP
Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
[TBL] [Abstract][Full Text] [Related]
27. Structural Insights into the Fluoroquinolone Resistance Mechanism of Shigella flexneri DNA Gyrase and Topoisomerase IV.
Tamanna ; Ramana J
Microb Drug Resist; 2016 Jul; 22(5):404-11. PubMed ID: 26859259
[TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
29. DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain.
Vranakis I; Sandalakis V; Chochlakis D; Tselentis Y; Psaroulaki A
Microb Drug Resist; 2010 Jun; 16(2):111-7. PubMed ID: 20438350
[TBL] [Abstract][Full Text] [Related]
30. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Nakase K; Sakuma Y; Nakaminami H; Noguchi N
Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
[TBL] [Abstract][Full Text] [Related]
31. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, molecular docking, and antibacterial evaluation of some novel flouroquinolone derivatives as potent antibacterial agent.
Patel MM; Patel LJ
ScientificWorldJournal; 2014; 2014():897187. PubMed ID: 25574496
[TBL] [Abstract][Full Text] [Related]
33. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
34. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
[TBL] [Abstract][Full Text] [Related]
35. Thiosemicarbazide Derivatives Decrease the ATPase Activity of
Kowalczyk A; Paneth A; Trojanowski D; Paneth P; Zakrzewska-Czerwińska J; Stączek P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918623
[TBL] [Abstract][Full Text] [Related]
36. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
[TBL] [Abstract][Full Text] [Related]
37. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
38. Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.
Richter SN; Giaretta G; Comuzzi V; Leo E; Mitchenall LA; Fisher LM; Maxwell A; Palumbo M
Nucleic Acids Res; 2007; 35(18):6075-85. PubMed ID: 17766248
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase.
Towle TR; Kulkarni CA; Oppegard LM; Williams BP; Picha TA; Hiasa H; Kerns RJ
Bioorg Med Chem Lett; 2018 Jun; 28(10):1903-1910. PubMed ID: 29661533
[TBL] [Abstract][Full Text] [Related]
40. Identification of promising anti-DNA gyrase antibacterial compounds using
Islam MA; Pillay TS
J Biomol Struct Dyn; 2020 Apr; 38(6):1798-1809. PubMed ID: 31084271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
